This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Prognosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Myelodysplasias are ultimately fatal. Death results from bleeding, infection, transformation to AML, or transfusion related iron-overload. Remission occurs in less than half of cases and typically, is short lived.

Risks of leukaemic transformation are:

  • 5-10% in refractory anaemia and in refractory anaemia with ringed sideroblasts
  • 40-50% in refractory anaemia with excess blasts
  • 100% in refractory anaemia with excess blasts in transformation

Median survival figures after diagnosis are:

  • 3-5 years in refractory anaemia and in refractory anaemia with ringed sideroblasts
  • 1-2 years in refractory anaemia with excess blasts and in chronic myelomonocytic leukaemia
  • less than 1 year in refractory anaemia with excess blasts in transformation

Poor prognostic factors for survival:

  • more than 5% blast cells in the marrow
  • very low blood counts
  • patients with abnormalities of chromosome 5 or 7 have a particularly poor prognosis. Certain subgroups, such as patients with an interstitial deletion of 5q associated with refractory anaemia and thrombocytosis, can expect a relatively good outcome (2)

Reference:

  1. Brandwein (1992). Myelodysplasia. Med. Int. 97.
  2. Jacobs RH, Cornbleet MA, Vardiman JW, et al. Prognostic implications of morphology and karyotype in myelodysplastic syndromes. Blood 1986; 67:1765–72

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.